Johnson & Johnson $JNJ Shares Sold by Vestor Capital LLC

Key Points

• Vestor Capital cut its Johnson & Johnson stake by 58% in the third quarter, selling 41,464 shares and retaining 29,988 shares worth about $7.94 million.
• J&J reported quarterly EPS of $2.59, above the $2.53 consensus, while revenue rose 5.9% year over year to $25.40 billion. The company set fiscal 2026 EPS guidance of $11.05–$11.15.
• The company reported encouraging early results for its investigational prostate cancer combination, and its oral psoriasis-arthritis treatment met the primary endpoint in a Phase 3 trial.

Vestor Capital LLC lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 58.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 29,988 shares of the company's stock after selling 41,464 shares during the quarter. Vestor Capital LLC's holdings in Johnson & Johnson were worth $7,939,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Wellington Management Group LLP raised its holdings in Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Deutsche Bank AG lifted its stake in Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock worth $3,977,506,000 after acquiring an additional 1,225,676 shares during the last quarter. Amundi grew its holdings in Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company's stock worth $3,277,163,000 after acquiring an additional 2,001,139 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Johnson & Johnson by 1.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company's stock worth $1,924,323,000 after acquiring an additional 148,497 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $1,967,399,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 2.0%

Shares of NYSE:JNJ opened at $281.86 on Tuesday. The firm has a 50 day simple moving average of $266.18 and a 200-day simple moving average of $248.62. Johnson & Johnson has a twelve month low of $185.12 and a twelve month high of $282.73. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $678.53 billion, a PE ratio of 42.71, a P/E/G ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the firm posted $2.80 EPS. The company's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's payout ratio is 81.21%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.16% of the company's stock.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a report on Monday, August 3rd. Scotiabank reiterated an "outperform" rating and set a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Johnson Rice lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Wednesday, October 21st. HSBC lifted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. Finally, UBS Group set a $270.00 price objective on Johnson & Johnson in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $275.92.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.